We analyzed the effects of different administration routes and application times of the BCG-Moreau strain on airway and lung inflammation and remodeling in a murine model of allergic asthma. BALB/c mice (n = 168) were divided into two groups. The first group received BCG-Moreau strain while the second group received saline using the same protocol. BCG or saline were intradermally or intranasally injected one or two months before the induction of asthma. Mice were further sensitized and challenged with ovalbumin or received saline. Twenty-four hours after the last challenge, BCG prevented the triggering of pro-inflammatory cytokines, probably by increasing Foxp3 and interleukin (IL)-10, modulating eosinophil infiltration and collagen fiber deposition, thus reducing airway hyperresponsiveness. In conclusion, BCGMoreau prevented lung remodeling in the present model of allergic asthma, regardless of administration route and time of vaccination. These beneficial effects may be related to the increase in regulatory T cells and to IL-10 production in tandem with decreased Th2 cytokines (IL-4, IL-5, and IL-13).
Introduction
Asthma is a chronic inflammatory disease affecting the airways and lung parenchyma (Bateman et al., 2008) , associated with remodeling characterized by the following ultrastructural changes: subepithelial fibrosis, mucous metaplasia, airway wall thickening, smooth muscle cell hypertrophy and hyperplasia, myofibroblast hyperplasia, vascular proliferation, and extracellular matrix abnormalities . These changes accelerate decline in lung function (Holgate, 2008) despite treatment with corticosteroids. Since lung remodeling is usually related to established inflammation, it may be hypothesized that early treatment with immunoregulatory agents could prevent damage.
Recent studies have demonstrated the Bacillus Calmette-Guérin (BCG) vaccine to be effective at reducing inflammation and hyperresponsiveness in animal models (Lagranderie et al., 2008) and in humans with asthma Koh, 2002, 2003; Cohon et al., 2007) . However, the effectiveness of this treatment seems to be affected by aspects of vaccine delivery: experimental studies report better control of the inflammatory process of asthma with intranasal administration compared to the intradermal route (Choi et al., 2007; Erb et al., 1998) , even though the latter is more commonly used in humans (Sarinho et al., 2010; Shirtcliffe et al., 2004) . Furthermore, there is controversy regarding the best time of BCG administration before induction of allergy (Erb et al., 1998; Nahori et al., 2001; Ozeki et al., 2011) . Additionally, a straindependent effect of BCG cannot be ruled out. In this line, the Moreau strain, which is widely used for tuberculosis control in Brazil (Benevolo-de-Andrade et al., 2005) , has been observed to induce an adaptive immunity while increasing cytokines from T helper 1 (Th1) and regulatory T cells (Treg) (Wu et al., 2007) , suggesting that this vaccine could be a potential tool for prevention of allergic asthma.
Based on the aforementioned, we used a murine model of allergic asthma to analyze the effects of different routes of administration and application times of the BCG-Moreau strain on pulmonary inflammation, remodeling process, and lung function. Moreover, possible mechanisms of action were investigated.
Materials and methods
This study was approved by the Ethics Committee of the Carlos Chagas Filho Institute of Biophysics, Health Sciences Center, Federal University of Rio de Janeiro, Brazil (CEUA-CCS, IBCCF 019).
Animal preparation
A total of 168 newly weaned male BALB/c mice (10-15 g) were randomly divided into two groups. The first group (n = 84) received 25 L of a solution of 10 6 UFC lyophilized BCG Moreau strain resuspended in saline while the second group (n = 84) received saline. BCG or saline were intradermally (n = 42) or intranasally (n = 42) injected one or two months before the induction of allergic asthma.
These groups were further randomized into two other groups. In the ovalbumin group (OVA), mice were immunized using an adjuvant-free protocol with intraperitoneal injection of ovalbumin (10 g in 0.1 mL sterile saline) on each of seven alternate days. Forty days after the beginning of sensitization, 20 g of OVA in 20 L sterile saline were intratracheally instilled. This procedure was performed three times at 3-day intervals. The control group (C) received saline using the same protocol.
Eighty-four animals were used for analysis of lung mechanics and histology, and a second group of 84 animals was used for analysis of airway responsiveness and bronchoalveolar lavage fluid (BALF). The BCG Moreau vaccine was donated by the Ataulpho de Paiva Foundation, Brazil.
Assessment of lung mechanics
Twenty-four hours after the last challenge, mice were sedated (diazepam 1 mg i.p.), anesthetized (thiopental sodium 20 mg/kg i.p.), tracheotomized, paralyzed (vecuronium bromide, 0.005 mg/kg i.v.), and mechanically ventilated with the following settings: respiratory frequency 100 breaths/min, tidal volume (V T ) 0.2 mL, and fraction of inspired oxygen (FiO 2 ) 0.21. The anterior chest wall was surgically removed and a positive end-expiratory pressure (PEEP) of 2 cmH 2 O was applied, and the lung mechanics were computed. At the end of the experiment, the lungs were prepared for histology and molecular biology. Airflow, volume and tracheal pressure (Ptr) were measured (Hsia et al., 2010) . In an open chest preparation, Ptr reflects transpulmonary pressure (PL). Lung static elastance and airway resistance were computed by the end-inflation occlusion method (Bates et al., 1985) using the ANA-DAT data analysis software (RHT-InfoData, Inc., Montreal, Quebec, Canada).
Airway responsiveness
Twenty-four hours after the last challenge, airway responsiveness was measured. Increasing doses of methacholine (Sigma Chemical Co., Saint Louis, MI, USA) (100, 300, 1000, 3000, and 10,000 g/kg) were administered via a silastic catheter placed in the jugular vein. Data were stored at 30 s, 1, 3, and 5 min after agonist injection. Shortly after each intravenous infusion of methacholine, the maximal increase in Ptr was reached, and the respective airflow was measured at this moment (Antunes et al., 2009 ). Respiratory system resistance (R) was obtained using the equation of motion of the respiratory system: Ptr(t) = E·V(t) + R·V (t), where (t) is time.
Lung histology
The right lung was removed, fixed in 4% buffered formaldehyde, paraffin-embedded, and cut into 4 m-thick slices, which were stained with hematoxylin and eosin (Vetec Química Fina, Rio de Janeiro, Brazil). Fraction area of collapsed and normal lung areas were determined by the point-counting technique at a magnification of 200× across 10 random, non-coincident microscopic fields (Hsia et al., 2010) . Points falling on collapsed or normal pulmonary areas were counted and divided by the total number of points in each microscopic field. Polymorphonuclear (PMN) and mononuclear (MN) cells and lung tissue were evaluated at 1000× magnification. Points falling on PMN and MN cells were counted and divided by the total number of points falling on lung tissue in each microscopic field.
Airway bronchoconstriction index was determined by counting the points falling on the airway lumen and those falling on airway smooth muscle and on the epithelium, at a magnification of 400×. The number of intercepts (NI) of the lines with the epithelial basal membrane is proportional to the airway perimeter, and the number of points (NP) falling on the airway lumen is proportional to airway area; thus, the magnitude of bronchoconstriction was computed as CI = NI/NP ½ . Measurements were performed in five airways from each animal at 400× magnification.
Collagen fibers (Picrosirius-polarization method) (Montes, 1996) were quantified in alveolar septa and airways with the aid of a digital analysis system and specific software (Image-Pro ® Plus 5.1 for Windows ® Media Cybernetics -Silver Spring, MD, USA) under 200× magnification. The area occupied by fibers was determined by digital densitometric recognition. To avoid any bias due to alveolar collapse, the areas occupied by collagen fibers in each alveolar septum were divided by the area. The results were expressed as the percentage of collagen fiber content per tissue area (%). Collagen fiber content was quantified in the whole circumference of the two largest, transversally cut airways present in the sections. Results were expressed as the area of collagen fibers divided by the perimeter of the basement membrane (m 2 /m).
Immunohistochemistry
Right lungs were fixed in 4% paraformaldehyde and embedded in paraffin for immunohistochemistry using monoclonal antibody against ␣-smooth muscle actin (Dako, Carpenteria, CA, USA) at a 1:500 dilution. The analysis was performed on the slides stained for ␣-smooth muscle actin applying the point-counting technique. Using a 121-point grid, we calculated the volume proportion of smooth-muscle-specific actin in terminal bronchioles and alveolar ducts as the relation between the number of points falling on actinstained and non-stained tissue. Measurements were done at 400× magnification in each slide (Hsia et al., 2010 ).
Transmission electron microscopy
Three 2 mm × 2 mm × 2 mm slices were cut from three different segments of the left lung and fixed [2.5% glutaraldehyde and phosphate buffer 0.1 M (pH 7.4)] for electron microscopy (JEOL 1010 Transmission Electron Microscope, Tokyo, Japan) analysis. For each electron microscopy image (20/animal), the following structural changes were analyzed: (a) shedding of surface epithelium, (b) airway edema, (c) eosinophil infiltration, (d) neutrophil infiltration, (e) disorganization of ciliated epithelial cells, (f) subepithelial fibrosis, (g) elastic fiber fragmentation, (h) smooth muscle hypertrophy, (i) myofibroblast hyperplasia, and (j) mucous cell hyperplasia. Pathologic findings were graded according to a 5-point semi-quantitative severity-based scoring system as: 0 = normal lung parenchyma, 1 = changes in 1-25%, 2 = changes in 26-50%, 3 = changes in 51-75%, and 4 = changes in 76-100% of examined tissue (Jeffery et al., 1992) .
Histological analysis was performed by a blinded pathologist.
Bronchoalveolar lavage fluid (BALF)
Total leukocyte count in BALF was performed in a Neubauer chamber with optical microscopy after diluting the samples in Türk solution. Differential leukocyte counts were performed in cytospin smears stained by the May-Grünwald-Giemsa method. The amount of interleukin (IL)-4, IL-5, IL-10, IL-12, IL-13, IL-17, interferon (IFN)-␥ and transforming growth factor (TGF)-␤ in the cell-free BALF was evaluated by ELISA in accordance with the manufacturer's instructions (Duo Set, R&D Systems, Minneapolis, USA).
Foxp3 expression
Quantitative real-time reverse transcription (RT) polymerase chain reaction (PCR) was performed to measure the relative levels of expression of Foxp3 genes in lung tissue (Yang et al., 2009) . Total RNA was extracted from the frozen tissues using the SV Total RNA Isolation System (Promega, Rio de Janeiro, Brazil) according to manufacturer instructions. RNA concentrations were measured in a Nanodrop ® ND-1000 spectrophotometer. Firststrand cDNA was synthesized from total RNA using the GoTaq ® 2-Step RT-qPCR System (Promega, Rio de Janeiro, Brazil), according to manufacturer recommendations. Relative mRNA levels were measured with a SYBR green detection system using a Mastercycler ep realplex 2 S (Eppendorf, São Paulo, Brazil). All samples were measured in triplicate. The relative amount of expression of each gene was calculated as the ratio of studied gene to a control gene (acidic ribosomal phosphoprotein P0 [36B4]) and expressed as fold changes relative to C or OVA groups. The following PCR primer was used: 5 -GAGCCAGAAGAGTTTCTCAAGC-3 and 5 -GCTACGATGCAGCAAGAGC-3 .
Statistical analysis
Two-way ANOVA followed by Tukey's test was used to compare all data considering route of administration and moment of injection as the study factors. A correlation between mechanical and histological data was analyzed using Spearman's correlation test. A p value less than 0.05 was considered significant. All tests were performed in GraphPad Prism 4.0 (GraphPad Software, San Diego, CA).
Results
The BCG-Moreau vaccine effectively reduced remodeling and lung inflammation, with positive effects on lung mechanics and morphometry, with no difference between administration route or time.
Remodeling
Collagen fiber content in the airway and lung parenchyma (Fig. 1A) , as well as the amount of ␣-smooth muscle actin in the terminal bronchiole and alveolar ducts (Fig. 1B) were higher in the SAL-OVA group compared to its respective control (SAL-C). BCG-Moreau therapy, regardless of route and moment of administration, prevented these alterations (Fig. 1A-C) . Since no significant difference on lung mechanics and histology were observed in mice treated with saline (data not shown), intradermally and intranasally treated animals were pooled in a single group.
In the SAL-OVA group, electron microscopy evidenced several ultra-structural changes in terminal bronchioles that are characteristic of asthma: shedding of surface epithelium, elastic fiber fragmentation, subepithelial fibrosis, disorganization of ciliated cells, myofibroblast hyperplasia, and smooth muscle hypertrophy. These ultrastructural changes were minimized by administration of BCG-Moreau before the asthma protocol (Table 1 and Fig. 2 ).
Lung inflammation
The inflammatory process was evaluated by counting total and differential cells in lung tissue and BALF (Fig. 3) . The number of polymorphonuclear cells in lung tissue and of eosinophils in BALF was significantly higher in the SAL-OVA group compared to the other groups (Fig. 3) . The administration of BCG-Moreau intradermally or intranasally, one or two months before asthma induction, attenuated the allergen-induced inflammatory process (Fig. 3) , with no statistical differences among BCG-treated groups.
Lung mechanics
Airway hyperresponsiveness, airway resistance (Raw), and lung static elastance (Est, L) were higher in SAL-OVA when compared to SAL-C (Fig. 4) . BCG minimized these mechanical changes, with no statistical differences among BCG-treated groups (Fig. 4) .
Lung histology and morphometry
The fraction area of alveolar collapse and the bronchoconstriction index were significantly higher in SAL-OVA than in SAL-C, and the administration of BCG-Moreau prevented these alterations (Fig. 5) . Considering all groups together, lung static elastance was well correlated with the fraction area of alveolar collapse, while airway resistance was correlated with the bronchoconstriction index (p < 0.05).
Mechanisms of action of BCG-Moreau vaccine on lung inflammation and remodeling
In order to investigate the possible mechanisms of action of the BCG-Moreau vaccine in the proposed allergic asthma model, cytokines with Th1 (IFN-␥, IL-12), Th2 (IL-4, IL-5 IL-13), Th17 (Th17) and Treg (IL-10), TGF-␤ profile and the mRNA expression of Foxp3 (Fig. 7) were measured. BCG led to IL-10 and Foxp3 increase, while reducing IL-4, IL-5, and IL-13 in OVA group (Figs. 6 and 7) . No significant changes were observed in the other mediators (data not shown).
Discussion
In the present study, intranasal and intradermal administration of BCG-Moreau vaccine, one or two months before asthma induction, minimized the inflammatory process. More importantly, BCG-Moreau vaccine prevented airway and lung parenchyma remodeling -as evidenced by the reduction of both collagen fiber content and percentage of smooth muscle-specific actin in terminal bronchioles and alveolar ducts, maintenance of airway epithelium integrity and by the decrease in subepithelial fibrosis, fragmentation of elastic fibers, and hyperplasia of myofibroblasts. Prevention of ultrastructural changes by BCG-Moreau treatment resulted in improved pulmonary function when compared to saline-treated OVA-challenged animals, as assessed by lung mechanics and airway hyperresponsiveness. Furthermore, these beneficial effects were associated with an increase in IL-10 and Foxp3, as well as with a reduction in Th2 cytokines.
BALB/c mice were chosen because of their greater ability to develop airway hyperresponsiveness and eosinophilia after chronic sensitizations and challenges with ovalbumin (Antunes et al., 2009 ). The present protocol was able to reproduce some aspects of human chronic asthma, such as airway hyperresponsiveness, eosinophilia, smooth muscle hypertrophy, and increased basement membrane thickness (Mestas and Hughes, 2004; Xisto et al., 2005) . In this study, the BCG protocol was begun as soon as the mice were weaned, since BCG is usually administered at a very young age (World Health Organization, 2004) . Experimental (Erb et al., 1998; Hopfenspirger and Agrawal, 2002; Major et al., 2002; Shen et al., 2008; Tukenmez et al., 1999) and clinical studies (Aaby et al., 2000; Alm et al., 1997; Bager et al., 2003; Choi and Koh, 2002) are controversial concerning the best time for BCG administration. Erb et al. found that the action of this vaccine decreased over time, and that the best results were achieved between two and four weeks before induction of the allergic process (Erb et al., 1998) . Conversely, Nahori et al. reported BCG effects lasting more than 8 weeks (Nahori et al., 2001 ), while Ozeki et al. observed a high amount of BCG mainly in the spleen up to 20 weeks after administration (Ozeki et al., 2011) . Based on the aforementioned, we administered BCGMoreau one or two months before asthma induction. Moreover, previous studies have also suggested an influence of BCG administration route on the vaccine's effectiveness (Choi et al., 2007; Erb et al., 1998; Hopfenspirger and Agrawal, 2002) . In this context, Erb et al. argue that BCG should be administered directly into the lung to promote better effects (Erb et al., 1998) . However, clinical trials have employed the intradermal route for BCG administration (Sarinho et al., 2010; Shirtcliffe et al., 2004) . We therefore compared the intradermal and intranasal routes. Erb et al. observed that the route of BCG administration influenced airway eosinophilia, with intranasal infection being superior to intraperitoneal or subcutaneous infection in its ability to reduce airway eosinophilia (Erb et al., 1998) . Conversely, our study demonstrated that the administration of BCG-Moreau intradermally or intranasally, one or two months before asthma induction, attenuated the allergen-induced inflammatory process, with no statistical differences between BCGtreated groups. Regarding the BCG vaccine dose, 10 6 CFU was used because it has been associated with a better immune response (Nahori et al., 2001; Yang et al., 2002) .
Previous genomic analyses of BCG vaccines demonstrate that there is genetic variability among the strains, leading to controversies regarding BCG efficacy (Davids et al., 2006; Wu et al., 2007) . However, the present results suggest that the protective efficacy of BCG-Moreau remains unaltered. According to recent molecular studies (Brosch et al., 2007) , BCG-Moreau, which has been used in Brazil for vaccine production since the 1920s (Berredo-Pinho et al., 2011) , belongs to the group of "older" strains that are closer to the attenuated strain originally derived by Calmette and Guérin. The BCG-Moreau strain is used in 5% of the BCG vaccines produced in the world (Benevolo-de-Andrade et al., 2005) . Allied to its availability (Hayashi et al., 2009 ) and meaningful role in vaccine preparations, the BCG-Moreau strain has immunogenic effects, as shown herein. In this line, this is the first study to date describing the ability of the BCG-Moreau strain to reduce inflammation and remodeling in experimental asthma. Studies have shown that the correlation between number of eosinophils and pulmonary airway reactivity has a critical impact on disease severity and number of exacerbations (Bousquet et al., 1990 ). An asthma model using eosinophil-deficient genetically modified PHIL mice demonstrated the essential role of eosinophils in airway hyperresponsiveness and pulmonary mucus accumulation (Lee et al., 2004) . Eosinophils may also contribute to airway remodeling, In this line, total ablation of eosinophil lineage reduced asthma-induced airway remodeling, as demonstrated by a decrease in peribronchiolar collagen deposition and fewer smooth musclespecific actin positive cells (Humbles et al., 2004) . Moreover, eosinophils produce a multitude of fibrogenic factors, such as TGF-␤, IL-11, IL-17, and IL-25 (Hamid and Tulic, 2009 ). In fact, eosinophils are the major source of TGF-␤ in asthmatic airways (Minshall et al., 1997; Ohno et al., 1996) , and they are an important source of numerous cytokines (e.g. IL-4, IL-5, IL-10, IL-13) that may influence the innate and adaptive immune responses associated with asthma (Hamid and Tulic, 2009) . Eosinophils also produce lipid mediators such as cysteinyl leukotrienes (Weller et al., 1983) and PGD 2 (Luna-Gomes et al., 2011), which contribute to the recruitment of innate and adaptive immunity cells, edema formation, and bronchoconstriction (Barnes, 2011) . Thus, an immunomodulatory therapy that reduces eosinophil recruitment may prevent inflammation and remodeling in allergic airways. BCG treatment reduced both mononuclear and PMN accumulation in the airways, but its most prominent effect seems to be on eosinophils, which were markedly reduced in BALF. This reduction may be associated with the decrease in IL-4, IL-5, and IL-13 (Hamid and Tulic, 2009 ). IL-13 produced by T cells, eosinophils, or innate helper cells (Hamid and Tulic, 2009; Holgate, 2012) has a central role in airway hyperresponsiveness development (Grunig et al., 1998; Wills-Karp et al., 1998) . BCG treatment completely abrogated IL-13 production in lungs of antigen-challenged mice, suggesting a causative relation with inhibition of lung parenchyma remodeling. Meanwhile, BCG treatment had no clear effect on TGF-␤ production in OVAchallenged mice. This lack of a clear-cut effect of BCG may reflect the somewhat controversial role of TGF-␤ in asthma. While TGF-␤ promotes goblet-cell and smooth muscle hyperplasia and subepithelial fibrosis, aggravating airway hyperresponsiveness (Halwani et al., 2011) , it may also limit airway remodeling by inhibiting tissue damage through inhibition of T and inflammatory cells (Holgate, 2012) .
The asthma model used in this study promoted a stereotypical Th2 cytokine profile with increase in cytokines related to airway and lung parenchyma inflammation and remodeling processes. BCG prevented asthma-associated alterations through modification of the adaptive immune response, which led to reduced levels of IL-4, IL-5, and IL-13 after antigen challenge. Bilenki et al. showed that BCG may reduce allergic inflammation of the airways through induction of a Th1-skewed response by mycobacterium activated dendritic cells. Transfer of dendritic cells from BCG-infected mice to mice sensitized with ragweed extract induced higher IFN-␥ and IL-12 while inhibiting IL-4, 5, -9, and -13 allergen-induced production by spleen and draining lymph node cell cultures, indicating a Th1-dominated immune response (Bilenki et al., 2010) . Several experimental studies in Th2-mediated diseases, including asthma, have shown an inhibition of Th2 compared to Th1 stimulus (Erb et al., 1998; Koh et al., 2001; Lagranderie et al., 2010; Tukenmez et al., 1999) . However, we did not find an increase in Th1 response-associated cytokines , thus indicating that a Th1-dependent inhibition of the allergic response is unlikely in our model. Such differences may arise from variations in study design, administration route of BCG, the specific BCG strain used, or the time elapsed between BCG administration and allergic challenge. We strived to reproduce as closely as possible the effects of BCG vaccination as done in public health campaigns around the world and particularly in Brazil.
Regulatory T cells (Tregs) also seem to counteract Th2 response in allergic subjects (Holgate, 2012) ; thus, induction of Tregs may represent an additional potential mechanism of BCG protection in asthma (Ahrens et al., 2009 ). Regardless of route or time of administration, BCG promoted an increase in Foxp3 gene expression in lung, suggesting an increase in Tregs. Furthermore, this increase in Foxp3 expression was independent of OVA sensitizations and challenges, as observed in the control groups. Increase in Foxp3 was paralleled by an increase in IL-10 production after antigen challenge; this suggests that BCG may reduce asthma inflammation by favoring accumulation of IL-10-producing Tregs in lungs. IL-10 (Bilenki et al., 2010; Gao et al., 2012) and Tregs (Gao et al., 2012) have also been shown to play a central role in BCG-induced decrease in allergic inflammation.
Asthma is a chronic inflammatory disease in which an exacerbated Th2 response is a central component that leads to changes in airway responsiveness and structure, as well as function impairment (Hamid and Tulic, 2009) . The focus of this study was to investigate if BCG-Moreau vaccination would have a positive impact on asthmatic airway function due to its immunomodulatory effects. BCG-Moreau vaccination completely abrogated allergeninduced increases in airway resistance and elastance due its effect of reducing bronchoconstriction and alveolar collapse, respectively. Moreover, it significantly inhibited the airway hyperresponsiveness that is a hallmark of asthma. Improvement of airway function was paralleled by inhibition of airway remodeling. The number of ␣-smooth muscle actin-positive myofibroblasts was reduced in lung tissue in BCG-OVA compared to SAL-OVA group, which may be associated with the observed reduction in collagen deposition and subepithelial fibrosis. The strengths of this paper are the use of BCG-Moreau, a strain widely used in children vaccination against tuberculosis in Brazil, and the modulation of lung remodeling. We believe that these strengths sufficiently counterbalance limitations such as the use of only one mouse strain (precluding extrapolation of the results to other strains) and the fact that a prophylactic approach was tested (making the results inapplicable to therapeutic management).
The present study has limitations that need to be addressed: (1) it has been described that the presence of viable organisms and granulomas in the lungs needs to be observed in order to characterize BCG immunization. However, this was not observed in our study, probably due analysis at a later time point, more than 60 days (Shaler et al., 2011) . Thus, further studies should be performed earlier, following BCG administration, to establish the granulomatous inflammation; (2) we hypothesized that the benefits we observed were associated with increased Treg cells or IL-10. However, for the study to be truly mechanistic, we should have demonstrated that the BCG vaccine could no longer protect against OVA-induced asthma in the absence of Tregs or IL-10. Further studies are therefore warranted to address this point.
Conclusion
In conclusion, in the present murine model of allergic asthma, the BCG-Moreau strain prevented airway and lung parenchyma remodeling, regardless of administration route and time of vaccination. These beneficial effects may be related to an increase in the number of Treg cells and in the production of IL-10 in tandem with a decrease in Th2 (IL-4, IL-5, and IL-13) cytokines.
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